检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:徐菀佚 郭明星 刘冉佳 崔向丽 XU Wanyi;GUO Mingxing;LIU Ranjia;CUI Xiangli(Department of Pharmacy,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China)
机构地区:[1]首都医科大学附属北京友谊医院药剂科,北京100050
出 处:《医药导报》2024年第12期2021-2025,共5页Herald of Medicine
摘 要:目的评估罗沙司他与达依泊汀α注射液治疗透析依赖性慢性肾病(DD-CKD)患者贫血的成本-效果,为此类疾病治疗提供卫生经济学参考。方法基于Markov模型模拟为期终生(20年)的DD-CKD患者贫血治疗,从中国医疗卫生体系角度估算罗沙司他与达依泊汀α注射液治疗的总成本,并将健康结果转换成质量调整生命年(QALY)。使用增量成本-效果比(ICER)来描述结果,并与支付意愿(WTP)进行比较,WTP阈值设定为257094元,是中国2023年人均国内生产总值(GDP)3倍。对结果进行单因素敏感性分析和概率敏感性分析,以测试模型的稳健性。结果罗沙司他总治疗成本为111902.41元,达依泊汀α注射液总治疗成本为52927.92元,使用罗沙司他的患者可获得的QALY为4.76,使用达依泊汀α注射液的患者可获得的QALY为4.74,ICER为每质量调整生命年2654912.45元,大于3倍人均GDP。因此,与达依泊汀α注射液相比,罗沙司他治疗DD-CKD患者贫血不具有成本-效果优势。结论在中国目前的经济情况下,与罗沙司他相比,达依泊汀α注射液治疗DD-CKD患者贫血具有成本-效果优势。Objective To evaluate the cost-effectiveness of roxadustat and darbepoetin alfa on treating renal anemia in dialysis-dependent chronic kidney disease(DD-CKD)patients,thus providing health economics reference for treatment of renal anemia.Methods A Markov model simulating the development and treatment of anemia in DD-CKD patients in a lifetime horizon(20 years)was constructed.Total costs of roxadustat and darbepoetin alfa injection were estimated from the perspective of Chinese healthcare system,with health outcomes converted into quality-adjusted life year(QALY).The incremental cost-effectiveness ratio(ICER)was used to describe the results.The willingness-to-pay(WTP)threshold was set at 257094 yuan,which was three times China’s gross domestic product(GDP)per capita in 2023.Sensitivity analyses were performed to test the uncertainties of the results.Results The total treatment costs of roxadustat and darbepoetin alfa injection were 111902.41 yuan and 52927.92 yuan respectively,corresponding to QALY values of 4.76 and 4.74 life-years.The incremental cost-effectiveness(ICER)was 2654912.45 yuan/QALY,which exceeded 3 times GDP per capita.Therefore,compared with darbepoetin alfa injection,roxadustat has no cost-effectiveness for patients with DD-CKD.Conclusion In the context of current economic development in China,darbepoetin alfa injection is more cost-effective than roxadustatin for treating anemia in DD-CKD patients.
关 键 词:罗沙司他 达依泊汀α注射液 透析依赖性慢性肾病贫血 MARKOV模型 成本-效果分析
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.249